Mobile

An open-label, multicenter, multinational Phase III follow-up study to investigate the long-term safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from tr...

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-000444-84

An open-label, multicenter, multinational Phase III follow-up study to investigate the long-term safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from treatment-associated dyskinesia

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To demonstrate the long-term safety of Sarizotan HCl 1 mg b.i.d. administered to Parkinson patients with dyskinesia.

Critère d'inclusion

  • Treatment-Associated Dyskinesia in Parkinson's Disease

Liens